VNDA Earnings

VNDA reported its earnings on 2026-02-11, showcasing a revenue of 57.22M against an estimate of 58.85M, resulting in a -2.78% surprise. The EPS was -0.46, surpassing the expected -2.18 by 78.9%. The stock experienced a -17.63% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following VNDA's earnings announcement on 2026-02-11, the stock price moved by -17.63% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, VNDA's stock price tends to shift by an average of -0.21% in the 10 days leading up to earnings and -5.66% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate VNDA's annual revenue to reach 61.47M, while the EPS is projected at -0.43. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VNDA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VNDA's stock price typically moves by -0.21% in the 10 days before its earnings and -5.66% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.43 and revenue of 61.47M.

The earnings call reveals mixed signals: a 9% revenue increase is positive, but a significant net loss and increased operating expenses are concerning. The Q&A section highlights optimism for FDA approvals, but uncertainties in commercialization and regulatory timelines persist. While there are positive developments, such as potential new drug approvals and ongoing clinical trials, the lack of clear guidance and increased expenses balance the sentiment to neutral.